Provention Bio is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. At Provention Bio, they approach autoimmune disease differently than traditional pharma, with a clear focus on early interception. Their lead investigational product candidate is currently under review by the U.S. FDA for the delay or prevention of clinical type 1 diabetes in at-risk individuals. The pipeline includes additional clinical-stage product candidates for autoimmune diseases, including celiac disease and lupus.
Market Place
